Liver Fat Reduction with Retatrutide: MASLD/NAFLD Implications

Background: MASLD and the Unmet Need

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease worldwide, affecting an estimated 25-30% of the global adult population. MASLD encompasses a spectrum from simple steatosis (excess fat accumulation in the liver) to steatohepatitis (MASH/NASH, with inflammation and hepatocyte injury), fibrosis, cirrhosis, and hepatocellular carcinoma.

The disease is closely tied to obesity, insulin resistance and metabolic syndrome. Despite how common and serious it is, treatment options for MASLD have long been limited. Lifestyle modification (weight loss through diet and exercise) remains the foundation of management, with pharmacological options only recently beginning to emerge. The FDA’s accelerated approval of resmetirom (a thyroid hormone receptor-beta agonist) for MASH with moderate to advanced fibrosis in 2024 was an important step, but much need remains across the MASLD spectrum.

Retatrutide’s Liver Fat Data

Phase 2 Obesity Trial: MASLD Substudy (Sanyal et al., Nature Medicine 2024)

Liver fat was measured with MRI-derived proton density fat fraction (MRI-PDFF), the current gold standard non-invasive method, in a substudy of the Phase 2 obesity trial. It enrolled 98 participants with MASLD and at least 10% liver fat. The primary endpoint was the relative change in liver fat at 24 weeks.

At 48 weeks, 89% (8 mg) and 93% (12 mg) had normal liver fat, though fewer participants were scanned at that point. Liver fat reductions were closely related to changes in body weight, abdominal fat and insulin sensitivity. The substudy is sometimes described as a separate “Phase 2a MASLD study”; it was part of the same obesity trial (NCT04881760).

Phase 2 Diabetes Trial

We have not found published liver fat results from the Phase 2 type 2 diabetes trial.

Mechanism of Liver Fat Reduction

Glucagon Receptor-Driven Hepatic Effects

The liver fat reduction observed with retatrutide is primarily attributed to the glucagon receptor component of its triple agonist mechanism. Liver cells carry many glucagon receptors, and activating them sets off several metabolic pathways that together reduce liver fat:

Enhanced fatty acid oxidation: GCGR activation stimulates mitochondrial beta-oxidation of fatty acids in hepatocytes. This increases the rate at which the liver burns stored fat as fuel, directly reducing the hepatic triglyceride pool. Key enzymes upregulated by glucagon signaling include carnitine palmitoyltransferase 1A (CPT1A), which controls the rate-limiting step of mitochondrial fatty acid import, and medium-chain acyl-CoA dehydrogenase (ACADM).

Reduced de novo lipogenesis: Glucagon signaling suppresses the activity of sterol regulatory element-binding protein 1c (SREBP-1c), a transcription factor that drives the expression of lipogenic enzymes including fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC). By reducing the synthesis of new fatty acids from carbohydrate substrates, glucagon receptor activation decreases one of the major inputs to the hepatic lipid pool.

Enhanced lipid export: GCGR activation promotes the hepatic secretion of very-low-density lipoproteins (VLDL), which transport triglycerides from the liver to peripheral tissues. This extra export route is another way the liver sheds triglycerides.

Complementary Mechanisms

While the glucagon receptor is the primary driver, the other components of retatrutide’s mechanism contribute to liver fat reduction through indirect mechanisms:

• Weight loss: Every unit of body weight lost reduces the delivery of free fatty acids from adipose tissue to the liver, decreasing one of the major sources of hepatic lipid accumulation
• Improved insulin sensitivity: GLP-1R and GIPR-mediated improvements in insulin sensitivity reduce the hyperinsulinemia that drives de novo lipogenesis in insulin-resistant states
• Reduced visceral adiposity: The preferential loss of visceral adipose tissue, which drains directly into the portal circulation, reduces the portal delivery of free fatty acids to the liver

Distinguishing Drug-Mediated vs. Weight-Mediated Effects

An important pharmacological question is whether retatrutide’s liver fat reduction is entirely attributable to weight loss or whether there is a direct, weight-independent hepatic effect mediated by glucagon receptor activation. Several lines of evidence suggest a direct hepatic contribution:

1. The magnitude of liver fat reduction with retatrutide appears to exceed what would be predicted from the degree of weight loss alone, based on published relationships between weight change and liver fat change in other interventions
2. Preclinical studies using glucagon receptor antagonists confirmed that the GCGR component independently contributes to hepatic lipid reduction
3. The liver fat reduction occurred relatively early in the treatment course, before the maximum weight loss was achieved, suggesting a pharmacological mechanism that acts in parallel with, not solely downstream of, weight loss

Clinical Implications for MASLD Treatment

Steatosis Resolution

The Phase 2 data show that retatrutide can clear fatty liver (liver fat back below the 5% MRI-PDFF threshold) in most patients at higher doses. That is a clinically meaningful outcome, as hepatic steatosis is the initial and most common manifestation of MASLD and its resolution may prevent progression to more advanced disease stages.

Potential for Steatohepatitis and Fibrosis Improvement

While the Phase 2 trials did not include liver biopsy endpoints, the dramatic reduction in liver fat content and the improvement in liver enzymes (ALT, AST) observed in some participants suggest that retatrutide may also improve hepatic inflammation and, potentially, fibrosis. However, these hypotheses require validation through dedicated MASLD/MASH trials with histological endpoints (liver biopsy before and after treatment), which are the regulatory standard for demonstrating efficacy in liver disease indications.

Comparison with Other Interventions

The magnitude of liver fat reduction observed with retatrutide in Phase 2 exceeds that reported for most other pharmacological interventions:

These cross-study comparisons are approximate and subject to the limitations of comparing across different trials with different populations and methodologies. Even so, they suggest retatrutide’s liver effects are among the strongest seen with any drug.

Future Directions

Dedicated MASLD/MASH Trials

The Phase 2 liver fat data have prompted strong interest in testing retatrutide specifically for MASLD/MASH, and dedicated trials are now underway. The SYNERGY trial is evaluating retatrutide for MASLD/MASH with histological endpoints, and the MACELD trial, launched in Q4 2025, is a dedicated liver disease Phase 3 study. These trials will assess histological improvement, specifically the resolution of steatohepatitis and/or improvement in fibrosis stage, which are the endpoints accepted by the FDA for MASH drug approval.

Long-Term Hepatic Safety

While the liver fat reduction is a favorable effect, the long-term consequences of chronic glucagon receptor agonism on hepatic function require continued monitoring. Parameters of interest include hepatic protein synthesis, bile acid metabolism, hepatic regenerative capacity, and the long-term trajectory of liver enzymes.

Biomarker Development

The use of MRI-PDFF as a non-invasive biomarker for liver fat has been valuable in retatrutide trials. Future studies may also incorporate advanced imaging techniques (MR elastography for fibrosis), circulating biomarkers (such as enhanced liver fibrosis [ELF] panels, fibrosis-4 [FIB-4] scores), and liver biopsy to give a fuller picture of liver health.

Summary

Retatrutide’s effect on liver fat is one of the most distinctive and potentially important parts of its profile. The approximately 82% relative reduction in liver fat at the highest dose, driven primarily by glucagon receptor-mediated hepatic effects, positions retatrutide as a potentially important therapeutic option for MASLD, a condition with enormous global prevalence and limited treatment options. The Phase 3 program and potential dedicated hepatic studies will be critical for determining whether these preliminary findings translate into confirmed clinical benefit for patients with liver disease.